基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效

doi:10.6040/j.issn.1671-7554.0.2021.0603

摘要/Abstract

摘要： 目的鉴定肺腺癌肿瘤干细胞相关基因亚型,构建肿瘤干性评分模型以预测肺腺癌免疫检查点抑制治疗疗效。方法从TCGA数据库下载肺腺癌RNA测序数据,使用“limma”包分析肺腺癌(535例)与癌旁组织(59例)中329个肿瘤干细胞相关基因的差异表达(FDR<0.05, |log₂ Fold Change|>2),利用差异基因鉴定肺腺癌肿瘤干细胞相关亚型,通过单因素Cox回归分析进一步筛选出肿瘤干细胞相关亚型之间对预后有意义的共同差异基因。基于主成分分析(PCA)算法,利用123个预后有意义的共同差异基因对TCGA与GEO合并后的630例肺腺癌患者进行肿瘤干性评分,利用Kaplan-Meier 曲线分析确定最佳截断值,将肺腺癌患者分成高、低肿瘤干性评分组(截断值为-1.91)。探究不同肺腺癌肿瘤干细胞相关亚型和肿瘤干性评分组在肿瘤微环境、免疫治疗方面的差异。结果鉴定出了36个差异表达基因和3个预后有统计学意义的肿瘤干细胞相关亚型(CSC-A、 CSC-B、 CSC-C)(P=0.033),其在免疫细胞浸润方面差异有统计学意义并与抗原递呈、细胞毒性作用等多条免疫通路相关。单因素Cox回归分析筛选出123个对预后有意义的共同差异基因,构建了肿瘤干性评分模型。低肿瘤干性评分组各类免疫细胞浸润程度普遍上升,PD1、PD-L1、CTLA4表达显著升高。无论是单独的抗CTLA4或抗PD1治疗,亦或是二者联合治疗,低肿瘤干性评分组的疗效都优于高肿瘤干性评分组,无免疫检查点抑制治疗时,高、低肿瘤干性评分组的疗效差异无统计学意义(P=0.060)。在抗PD-L1和抗PD1的两个独立免疫治疗队列中,低肿瘤干性评分组的反应率均高于高肿瘤干性评分组(抗PD-L1治疗队列反应率:50% vs 20%;抗PD1治疗队列反应率:23% vs 0%)。结论肿瘤干性评分模型在预测肺腺癌患者免疫检查点抑制治疗疗效方面具有潜在价值,有望为肺腺癌患者免疫检查点抑制治疗提供理论依据。

关键词: 肿瘤干性, 免疫治疗, 肺腺癌, 肿瘤微环境, 免疫检查点

Abstract: Objective To predict immune checkpoint blockade(ICB)response in lung adenocarcinoma(LUAD)by identifying LUAD subtypes related to cancer stem cells and constructing a stemness-based scoring model. Methods LUAD RNA-seq data were obtained from TCGA database. By “limma” package, 329 differentially expressed genes(DEGs)related to cancer stem cells between LUAD(535 cases)and adjacent tissues(59 cases)were identified to classify LUAD into different subtypes(FDR<0.05, |log₂ Fold Change|>2). By univariate Cox regression analysis, the common prognostic DEGs among different subtypes were further screened out. Using principal component analysis(PCA)and the 123 common prognostic DEGs, a stemness-based scoring model was established for 630 LUAD patients from TCGA and GEO. The cutoff value, determined by Kaplan-Meier curves analysis, was used to stratify LUAD patients into high- and low-score groups(cutoff value=-1.91). Furthermore, difference of distinct subtypes and stemness-based scores on tumor microenvironment(TME)and ICB therapy were analyzed. Results Thirty-six differentially expressed genes and three LUAD subtypes related to cancer stem cells(CSC-A, CSC-B, and CSC-C)were identified, overall survival rates of which were statistically different(P=0.033). The three subtypes greatly affected immune infiltration levels and were associated with multiple immune pathways, such as antigen presentation and cytotoxicity. A total of 123 common prognostic genes(P<0.05)were screened out to construct stemness-based scoring model by univariate Cox regression. In the low-score group, the infiltration of various immune cells and mRNA expressions of PD1, PD-L1 and CTLA4 were up-regulated. No matter anti-CTLA4 or anti-PD1 treatment alone, or combination of them, efficacy of the low-score group was better than that of the high-score group, and there was no significant difference in the efficacy of the two groups without ICB(P=0.060). In the anti-PD-L1 and anti-PD1 immunotherapy cohorts, the response rates of the low-score group were higher than that of the high-score group(the response rate of the anti-PD-L1 treatment cohorts: 50% vs 20%; the response rate of anti-PD1 treatment cohorts: 23% vs 0%). Conclusion Stemness-based scoring model has a potential to predict the efficacy of ICB therapy in LUAD patients, which is expected to provide a theoretical basis for ICB therapy in LUAD patients.

Key words: Cancer stemness, Immunotherapy, Lung adenocarcinoma, Tumor microenvironment, Immune checkpoint

中图分类号:

R734.2

庞兆飞,柳勇,赵小刚,闫涛,陈效伟,杜贾军. 基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效[J]. 山东大学学报 (医学版), 2021, 59(11): 19-28.

PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases[J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.

参考文献

[1] Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma[J]. Cell Death Dis, 2018, 9(2):117.
[2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[3] Zhao Z, Zheng L, Chen W, et al. Delivery strategies of cancer immunotherapy: recent advances and future perspectives[J]. J Hematol Oncol, 2019, 12(1): 126.
[4] Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018, 24(10): 1550-1558.
[5] Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017, 168(4): 707-723.
[6] Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell(CSC)resistance drivers[J]. Life Sci, 2019, 234: 116781. doi: 10.1016/j.lfs.2019.116781.
[7] Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications[J]. Annu Rev Pathol, 2016, 11: 47-76. doi: 10.1146/annurev-pathol-012615-044438.
[8] Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, et al. Cancer stem cell metabolism[J]. Breast Cancer Res, 2016, 18(1): 55.
[9] Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance[J]. Theranostics, 2020, 10(19): 8721-8743.
[10] Quaglino E, Conti L, Cavallo F. Breast cancer stem cell antigens as targets for immunotherapy[J]. Semin Immunol, 2020, 47: 101386. doi: 10.1016/j.smim.2020.101386.
[11] Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab[J]. Cell, 2017, 171(4): 934-949.e16.
[12] Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018, 554(7693): 544-548.
[13] Shi J, Hua X, Zhu B, et al. Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study[J]. PLoS Med, 2016, 13(12): e1002162.
[14] Spella M, Stathopoulos GT. Immune resistance in lung adenocarcinoma[J]. Cancers(Basel), 2021, 13(3): 384.
[15] Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor(Sintilimab)in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.
[16] Clara JA, Monge C, Yang Y, et al. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update[J]. Nat Rev Clin Oncol, 2020, 17(4): 204-232.
[17] Najafi M, Farhood B, Mortezaee K. Cancer stem cells(CSCs)in cancer progression and therapy[J]. J Cell Physiol, 2019, 234(6): 8381-8395.
[18] Raghavan S, Mehta P, Xie Y, et al. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments[J]. J Immunother Cancer, 2019, 7(1): 190.
[19] Miao Y, Yang H, Levorse J, et al. Adaptive immune resistance emerges from tumor-initiating stem cells[J]. Cell, 2019, 177(5): 1172-1186.e14.
[20] 王海洋, 董军. 靶向胶质瘤干细胞及其微环境的免疫治疗进展[J]. 中国现代神经疾病杂志, 2020, 20(2): 86-95. WANG Haiyang, DONG Jun. Immunotherapy targeting glioma stem cells and its microenvironment[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(2): 86-95.
[21] Hinshaw DC, Shevde LA. The Tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566.
[22] Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application[J]. J Hematol Oncol, 2017, 10(1): 58.
[23] Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566.
[24] 马冉冉, 韩琛, 王朝霞, 等. 人参总皂苷调控NK细胞活性促进5-氟尿嘧啶抗肿瘤的作用[J]. 山东大学学报(医学版), 2018, 56(4): 43-50. MA Ranran, HAN Chen, WANG Zhaoxia, et al. Total saponins of Panax ginseng promoting the anticancer activity of 5-Fluorouracil by mediating NK cell activity[J]. Journal of Shandong University(Health Sciences), 2018, 56(4): 43-50.
[25] Kurachi M. CD8 T cell exhaustion[J]. Semin Immunopathol, 2019, 41(3): 327-337.
[26] Zhang B, Chikuma S, Hori S, et al. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model[J]. Proc Natl Acad Sci U S A, 2016, 113(30): 8490-8495.
[27] Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update[J]. Immunotherapy, 2016, 8(3): 279-298.
[28] Bassi R, Fornoni A, Doria A, et al. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease[J]. Diabetologia, 2016, 59(1): 21-29.
[29] Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nature reviews Cancer, 2016, 16(5): 275-287.
[30] Walk EE, Yohe SL, Beckman A, et al. The cancer immunotherapy biomarker testing landscape[J]. Arch Pathol Lab Med, 2020, 144(6): 706-724.
[31] Liu JN, Kong XS, Huang T, et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study[J]. Front Immunol, 2020, 11: 2048. doi: 10.3389/fimmu.2020.02048.

相关文章 15

[1]	殷悦,莫振飞,吴培昕,刘金霞,魏元辉,任佳博,李春笋. GPX1基因在肺癌中的表达特征及其对肺腺癌细胞增殖、迁移、侵袭、凋亡的影响[J]. 山东大学学报 (医学版), 2026, 64(1): 65-73.
[2]	韩觉明,王晖,吴倩,郑慧玲,朱琳. B4GALNT4促进肺腺癌细胞增殖、迁移和侵袭能力[J]. 山东大学学报 (医学版), 2025, 63(7): 23-31.
[3]	蔡佳莹,王靖婷,王增萍,王璟,郏雁飞,马晓丽. α5-nAChR对慢性应激肺腺癌荷瘤小鼠疑核c-Fos表达的影响[J]. 山东大学学报 (医学版), 2025, 63(4): 69-74.
[4]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[5]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[6]	田丽君,桑玉洁,孙瑜婧,韩冰,秦成勇,祁建妮. 全身免疫炎症指数对原发性肝癌患者免疫检查点抑制剂治疗相关不良反应的预测价值[J]. 山东大学学报 (医学版), 2024, 62(6): 48-53.
[7]	王靖婷,王璟,鲁艺,李静坦,李强,郏雁飞,马晓丽. α5-nAChR与MHC-I在肺腺癌中的表达及相关性[J]. 山东大学学报 (医学版), 2024, 62(5): 72-78.
[8]	杨闯,张荣雨,宋彬,王程君,赵文,玄甜甜,李际盛. 阿美替尼一线治疗EGFR突变肺腺癌伴大疱性类天疱疮1例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(12): 32-37.
[9]	宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[10]	孟健丽,王庆港. 生物信息学方法探讨VPS72在肺腺/鳞癌中的表达及潜在作用机制[J]. 山东大学学报 (医学版), 2023, 61(8): 40-49.
[11]	杜圣红,李晓梅,陈晨,王玲. 鼻型弥漫大B细胞淋巴瘤合并肺腺癌1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(8): 111-115.
[12]	刘士标,张淑君,李培龙,杜鲁涛,王传新. cg20657709位点甲基化对肺腺癌早期诊断的初步探讨[J]. 山东大学学报 (医学版), 2023, 61(4): 18-25.
[13]	胡立勇,钟浩,房娟娟,国巍,张雨露,范医东. 基于数据库分析CCR基因对肾透明细胞癌预后的预测价值[J]. 山东大学学报 (医学版), 2023, 61(4): 49-55.
[14]	赵启迪,王凯,赵小刚,闫涛,王亚东,杜贾军. 基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型[J]. 山东大学学报 (医学版), 2023, 61(10): 23-37.
[15]	张建树,张瀚文,赵文静. 长链非编码RNA ZNF528-AS1促进乳腺癌他莫昔芬耐药及进展转移[J]. 山东大学学报 (医学版), 2023, 61(1): 17-26.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed